Published in Pediatr Nephrol on August 16, 2005
Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis. Clin Exp Immunol (2007) 0.85
Efficacy and safety of angiotensin II receptor type 1 antagonists in children and adolescents. Pediatr Nephrol (2010) 0.76
Retracted Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet (2003) 7.69
Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis (2001) 2.49
Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol (2003) 1.70
Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone--a report of the International Study of Kidney Disease in Children. Pediatr Nephrol (1992) 1.10
Comparative effects of ACE inhibition and angiotensin II receptor blockade in the prevention of renal damage. Kidney Int Suppl (2002) 0.86
Additive antiproteinuric effect of ACE inhibitor and losartan in IgA nephropathy. Pediatr Nephrol (2002) 0.85
The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises. Kidney Int (2003) 0.83
Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy. Pediatr Int (2004) 0.81
Remission of membranoproliferative nephritis with angiotensin converting enzyme inhibition and receptor blockade. Pediatr Nephrol (2003) 0.78
Effects of angiotensin converting enzyme inhibitor on renal function in patients of membranoproliferative glomerulonephritis with mild to moderate renal insufficiency. J Assoc Physicians India (2002) 0.76